Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.41 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.39 |
| ▸ | PGK1 | P00558 | 1/20 | 0.38 |
| ▸ | PGK2 | P07205 | 1/20 | 0.38 |
| ▸ | HINT1 | P49773 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3656038 | 0.92 | CYP2C19 (0.41) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL3656043 | 0.92 | CYP2C19 (0.41) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL18947545 | 0.88 | ADORA3 (0.36) | CYP2C19ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL3660257 | 0.85 | PI4KA (0.40) | ADORA3ADORA1SLC29A1ADORA2AADORA2B | |
| SCHEMBL15203779 | 0.84 | CYP2C19 (0.43) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL12170652 | 0.84 | CYP2C19 (0.43) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL15203741 | 0.83 | CYP2C19 (0.43) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL15203742 | 0.83 | CYP2C19 (0.43) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 | |
| SCHEMBL3662558 | 0.82 | ADORA3 (0.51) | ADORA3ADORA1HSP90B1SLC29A1ADORA2A | |
| SCHEMBL18948278 | 0.82 | CYP2C19 (0.38) | CYP2C19ADORA3ADORA1HSP90B1SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2227482-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | Pharmasset, Inc. (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009067409-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2009-05-28 | — | — | WO | claimed |
| US-9676808-B2 | 2′,4′-substituted nucleosides as antiviral agents | GILEAD PHARMASSET LLC (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160280735-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-09-29 | — | — | US | disclosed |
| US-20160280735-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-09-29 | — | — | US | disclosed |
| EP-2848624-A1 | 2',4'-substituted nucleosides as antiviral agents | Gilead Pharmasset LLC (US) | 2015-03-18 | — | — | EP | disclosed |
| EP-2631239-A1 | 2',4'-substituted nucleosides as antiviral agents | Gilead Pharmasset LLC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-20120232029-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20120232029-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2012-09-13 | — | — | US | disclosed |
| US-20090318380-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090318380-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | PHARMASSET, INC. (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318380-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | HAVCR2, NUDT1, NT5C3B | CYP2C19 1263/4885ADORA3 102/4885ADORA1 157/4885 |
| US-20120232029-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | HAVCR2, NUDT1, NT5C3B | CYP2C19 1263/4885ADORA3 102/4885ADORA1 157/4885 |
| US-20160280735-A1 | 2',4'-SUBSTITUTED NUCLEOSIDES AS ANTIVIRAL AGENTS | HAVCR2, NUDT1, NT5C3B | CYP2C19 1263/4885ADORA3 102/4885ADORA1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.